ELOX Stock — Eloxx Pharmaceuticals Inc.: Cash, EV, Pipeline

What they do

Our immediate focus is to advance the clinical development of our lead product candidate, exaluren, for the treatment of rare kidney diseases and, through our collaboration with Almirall, S.A. (“Almirall”), ZKN-013 for the treatment of rare skin diseases. Exaluren is a novel eukaryotic ribosome-selective glycoside (“ERSG”) product candidate that is designed to induce premature termination codon (“PTC”) readthrough in the presence of NMs and promote the restoration of full-length proteins.

Source: 10-K FY2025 via SEC EDGAR

Share price

$12.50

Market cap

$50.5M

Cash

$62.0M

Enterprise value

-$11.5M

Balance sheet

Cash	$62.0M
Debt	$0.0M
Net cash	$62.0M
Enterprise value	-$11.5M
Basic shares	4.0M shares
Fully diluted shares	8.6M shares
Fully diluted market cap	$107.8M
Cash per share	$15.35
Quarterly burn	$4.8M
Cash runway	12.9 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

4.0M

Pre-funded warrants

3.5M

Options

1.0M

RSUs

0.0M

Warrants

0.1M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

8.6M

Cap table as of 2026-08-07.

Price history

Loading ELOX daily closes…

Loading price history…

Next catalyst

Exaluren · Aug 11 - Sep 22 in 9 mo · Phase 2 · Alport Syndrome, X-Linked; Alport Syndrome, Autosomal Recessive

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Aug 11 - Sep 22 in 9 mo	Exaluren	Phase 2	Alport Syndrome, X-Linked; Alport Syndrome, Autosomal Recessive	—
GUIDEDDec 1-31 in 13 mo	exaluren Phase 2b in nonsense mutation Alport syndrome; planned Phase 2 in ADPKD	Phase 2b	nonsense mutation Alport syndrome	mid-2027 (initial 16-week NMAS); end 2027 (final NMAS); mid-2028 (ADPKD)

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

exaluren

Phase 2 · Active Modality: small molecule (oral/injectable; ribosome modulator)

Target premature termination codons (nonsense mutations)

Partnerships n/a; licensed from TRDF (up to $6.5M milestones per product, low-to-mid single-digit royalties); CFF funding obligations reduced to <1% of net sales

Indications

Alport syndrome with nonsense mutations (NMAS) (Phase 2)
Autosomal dominant polycystic kidney disease with nonsense mutations (nmADPKD) (Preclinical)

Catalysts

— Q3 2026
— mid-2027
— end of 2027
— 2027
— mid-2028

Status note Lead candidate; completed Phase 2a (n=3) in NMAS. Prior Phase 2 studies in CF and nephropathic cystinosis also completed; program focus shifted to kidney indications. Orphan designations: FDA (Alport syndrome), EU (ADPKD, Jul 2026).

ZKN-013

Phase 1 · Active Modality: small molecule (oral ribosome modulating agent)

Target premature termination codons (nonsense mutations)

Partnerships Almirall, S.A.: exclusive global license (Mar 2024); $3M upfront + $3M development milestone received 2024; up to ~$470M additional milestones; tiered royalties. Almirall responsible for development/commercialization.

Indications

Recessive dystrophic epidermolysis bullosa (RDEB) with nonsense mutations (Phase 1)
Junctional epidermolysis bullosa (JEB) with nonsense mutations (Phase 1)

Status note Partnered program; Almirall conducting Phase 1 in healthy volunteers. Rights revert to Eloxx if Almirall terminates for convenience.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Exaluren
Lead indication	Alport Syndrome, X-Linked
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07523581	Phase 2	Recruiting	Sponsor	ELOX	—	Alport Syndrome, X-Linked; Alport Syndrome, Autosomal Recessive	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Eloxx Pharmaceuticals, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
EcoR1 Capital	400,000	+400,000	0.28%	2026-08-14
Stonepine Capital	397,160	+397,160	4.20%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ELOX — Eloxx Pharmaceuticals Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

ELOX — Eloxx Pharmaceuticals Inc.